LON:AMYT

Amryt Pharma (AMYT) Share Price, News & Analysis

GBX 143
-19.00 (-11.73%)
(As of 01/10/2022)
Today's Range
143
155
50-Day Range
143
143
52-Week Range
135
230
Volume
90,727 shs
Average Volume
469,552 shs
Market Capitalization
£457.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AMYT stock logo

About Amryt Pharma Stock (LON:AMYT)

Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate, which is in Phase 3 EASE trial for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 that is in preclinical stage for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

AMYT Stock Price History

AMYT Stock News Headlines

Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
Amryt Supports Acromegaly Awareness Day 2022
AMYT Amryt Pharma plc
Amryt Pharma PLC ADR Stock Quote AMYT
Amryt Announces New Patent for Mycapssa®
Amryt Pharma PLC Rings the Opening Bell
See More Headlines
Receive AMYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amryt Pharma and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
2,020
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£210.24 million
Cash Flow
GBX 38.90 per share
Book Value
GBX 96.60 per share

Miscellaneous

Free Float
N/A
Market Cap
£457.11 million
Optionable
Not Optionable
Beta
N/A
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Joseph A. Wiley (Age 50)
    CEO & Director
    Comp: $1.72M
  • Mr. Rory P. Nealon (Age 53)
    CFO, COO & Company Sec.
    Comp: $931k
  • Ms. Elizabeth Varki Jobes J.D. (Age 54)
    Sr. VP & Global Chief Compliance Officer
  • Mr. John McEvoy
    Gen. Counsel
  • Mr. Stephen Joyce
    VP of Global Marketing
  • Ms. Julie Eastwood
    Head of HR
  • Ms. Derval O'Carroll
    Head of Regulatory Affairs
  • Mr. Gerry Gilligan
    Head of Manufacturing Supply Chain
  • Dr. Mark Sumeray (Age 55)
    Chief Medical Officer
  • Mr. David Allmond
    Chief Commercial Officer

AMYT Stock Analysis - Frequently Asked Questions

How have AMYT shares performed in 2024?

Amryt Pharma's stock was trading at GBX 143 on January 1st, 2024. Since then, AMYT shares have increased by 0.0% and is now trading at GBX 143.
View the best growth stocks for 2024 here
.

What other stocks do shareholders of Amryt Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amryt Pharma investors own include The Parkmead Group (PMG), Himax Technologies (HIMX), Atalaya Mining (ATYM), Concepta PLC (CPT.L) (CPT), Faroe Petroleum (FPM), Vectura Group (VEC), Xcite Energy (XEL), Bowleven (BLVN), BTG (BTG) and Cavium (CAVM).

How do I buy shares of Amryt Pharma?

Shares of AMYT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:AMYT) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners